(GILD) Gilead Sciences - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NASDAQ (USA) | Market Cap: 160.883m USD | Total Return: 25.4% in 12m

Antivirals, Oncology, Cell Therapy, Immunotherapy
Total Rating 65
Safety 81
Buy Signal -0.67
Drug Manufacturers - General
Industry Rotation: +6.8
Market Cap: 161B
Avg Turnover: 812M
Risk 3d forecast
Volatility29.3%
VaR 5th Pctl5.05%
VaR vs Median4.43%
Reward TTM
Sharpe Ratio0.96
Rel. Str. IBD39.3
Rel. Str. Peer Group27.8
Character TTM
Beta0.196
Beta Downside0.031
Hurst Exponent0.531
Drawdowns 3y
Max DD26.59%
CAGR/Max DD0.84
CAGR/Mean DD3.10
EPS (Earnings per Share) EPS (Earnings per Share) of GILD over the last years for every Quarter: "2021-03": 2.08, "2021-06": 1.87, "2021-09": 2.65, "2021-12": 0.69, "2022-03": 2.12, "2022-06": 1.58, "2022-09": 1.9, "2022-12": 1.67, "2023-03": 1.37, "2023-06": 1.66, "2023-09": 2.29, "2023-12": 1.72, "2024-03": -1.32, "2024-06": 2.01, "2024-09": 2.02, "2024-12": 1.9, "2025-03": 1.81, "2025-06": 2.01, "2025-09": 2.47, "2025-12": 1.86, "2026-03": 2.03,
EPS CAGR: 6.91%
EPS Trend: 13.8%
Last SUE: 0.80
Qual. Beats: 0
Revenue Revenue of GILD over the last years for every Quarter: 2021-03: 6423, 2021-06: 6217, 2021-09: 7421, 2021-12: 7244, 2022-03: 6590, 2022-06: 6260, 2022-09: 7042, 2022-12: 7389, 2023-03: 6352, 2023-06: 6599, 2023-09: 7050, 2023-12: 7114, 2024-03: 6686, 2024-06: 6953, 2024-09: 7545, 2024-12: 7569, 2025-03: 6667, 2025-06: 7081, 2025-09: 7769, 2025-12: 7924, 2026-03: 6960,
Rev. CAGR: 2.87%
Rev. Trend: 54.0%
Last SUE: 0.17
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: GILD Gilead Sciences

Gilead Sciences, Inc. is a California-based biopharmaceutical company focused on developing and commercializing therapeutics for life-threatening diseases. Its core portfolio centers on HIV-1 infection treatments, including Biktarvy and Descovy, alongside specialized therapies for chronic hepatitis B, C, and primary biliary cholangitis. The company also maintains a significant presence in oncology through CAR T-cell therapies like Yescarta and Tecartus, and provides the antiviral Veklury for COVID-19 treatment.

The biotechnology sector relies heavily on a capital-intensive research and development model, where long-term growth is driven by the successful navigation of clinical trial phases and patent protection for novel molecular entities. Gilead extends its pipeline through a network of strategic collaborations with global pharmaceutical firms and specialized biotech entities to co-develop immunotherapies and small molecule treatments. Investors can explore more comprehensive financial metrics for GILD on ValueRay.

Headlines to Watch Out For
  • Biktarvy dominance and Sunlenca adoption drive long-term HIV market share stability
  • Trodelvy sales growth and oncology pipeline expansion diversify revenue beyond virology
  • Declining Veklury demand creates significant year-over-year revenue headwinds for COVID-19 portfolio
  • High-stakes clinical trial results for Arcus Biosciences partnership impact future valuation
  • Strategic acquisitions and liver disease drug approvals offset upcoming HIV patent expirations
Piotroski VR‑10 (Strict) 7.5
Net Income: 9.22b TTM > 0 and > 6% of Revenue
FCF/TA: 0.18 > 0.02 and ΔFCF/TA 0.73 > 1.0
NWC/Revenue: 30.82% < 20% (prev 15.86%; Δ 14.96% < -1%)
CFO/TA 0.19 > 3% & CFO 10.81b > Net Income 9.22b
Net Debt (14.55b) to EBITDA (13.33b): 1.09 < 3
Current Ratio: 1.97 > 1.5 & < 3
Outstanding Shares: last quarter (1.25b) vs 12m ago -0.40% < -2%
Gross Margin: 79.35% > 18% (prev 0.78%; Δ 7.86k% > 0.5%)
Asset Turnover: 52.76% > 50% (prev 50.92%; Δ 1.84% > 0%)
Interest Coverage Ratio: 8.87 > 6 (EBITDA TTM 13.33b / Interest Expense TTM 1.00b)
Altman Z'' 3.40
A: 0.16 (Total Current Assets 18.64b - Total Current Liabilities 9.48b) / Total Assets 56.28b
B: 0.25 (Retained Earnings 14.13b / Total Assets 56.28b)
C: 0.16 (EBIT TTM 8.91b / Avg Total Assets 56.36b)
D: 0.43 (Book Value of Equity 14.21b / Total Liabilities 32.85b)
Altman-Z'' Score: 3.40 = A
Beneish M -3.04
DSRI: 1.04 (Receivables 4.74b/4.39b, Revenue 29.73b/28.73b)
GMI: 0.99 (GM 79.35% / 78.29%)
AQI: 0.94 (AQ_t 0.57 / AQ_t-1 0.60)
SGI: 1.03 (Revenue 29.73b / 28.73b)
TATA: -0.03 (NI 9.22b - CFO 10.81b) / TA 56.28b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of GILD shares? As of May 19, 2026, the stock is trading at USD 129.67 with a total of 5,174,987 shares traded.
Over the past week, the price has changed by -2.88%, over one month by -4.56%, over three months by -14.62% and over the past year by +25.39%.
Is GILD a buy, sell or hold? Gilead Sciences has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy GILD.
  • StrongBuy: 15
  • Buy: 4
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the GILD price?
Analysts Target Price 158 21.8%
Gilead Sciences (GILD) - Fundamental Data Overview as of 18 May 2026
P/E Trailing = 17.6299
P/E Forward = 15.0376
P/S = 5.4104
P/B = 6.9341
P/EG = 0.3665
Revenue TTM = 29.73b USD
EBIT TTM = 8.91b USD
EBITDA TTM = 13.33b USD
Long Term Debt = 22.13b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 22.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.55b USD (from netDebt column, last quarter)
Enterprise Value = 173.24b USD (160.88b + Debt 22.17b - CCE 9.82b)
Interest Coverage Ratio = 8.87 (Ebit TTM 8.91b / Interest Expense TTM 1.00b)
EV/FCF = 16.94x (Enterprise Value 173.24b / FCF TTM 10.23b)
FCF Yield = 5.90% (FCF TTM 10.23b / Enterprise Value 173.24b)
FCF Margin = 34.40% (FCF TTM 10.23b / Revenue TTM 29.73b)
Net Margin = 30.99% (Net Income TTM 9.22b / Revenue TTM 29.73b)
Gross Margin = 79.35% ((Revenue TTM 29.73b - Cost of Revenue TTM 6.14b) / Revenue TTM)
Gross Margin QoQ = 79.24% (prev 79.51%)
Tobins Q-Ratio = 3.08 (Enterprise Value 173.24b / Total Assets 56.28b)
Interest Expense / Debt = 1.08% (Interest Expense 240.0m / Debt 22.17b)
Taxrate = 21.67% (559.0m / 2.58b)
NOPAT = 6.98b (EBIT 8.91b * (1 - 21.67%))
Current Ratio = 1.97 (Total Current Assets 18.64b / Total Current Liabilities 9.48b)
Debt / Equity = 0.94 (Debt 22.17b / totalStockholderEquity, last quarter 23.52b)
Debt / EBITDA = 1.09 (Net Debt 14.55b / EBITDA 13.33b)
Debt / FCF = 1.42 (Net Debt 14.55b / FCF TTM 10.23b)
Total Stockholder Equity = 21.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.35% (Net Income 9.22b / Total Assets 56.28b)
RoE = 42.20% (Net Income TTM 9.22b / Total Stockholder Equity 21.84b)
RoCE = 20.27% (EBIT 8.91b / Capital Employed (Equity 21.84b + L.T.Debt 22.13b))
RoIC = 15.10% (NOPAT 6.98b / Invested Capital 46.25b)
WACC = 5.96% (E(160.88b)/V(183.06b) * Re(6.67%) + D(22.17b)/V(183.06b) * Rd(1.08%) * (1-Tc(0.22)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 2.33 | Cagr: -0.07%
[DCF] Terminal Value 86.04% ; FCFF base≈10.07b ; Y1≈9.78b ; Y5≈9.79b
[DCF] Fair Price = 223.3 (EV 291.82b - Net Debt 14.55b = Equity 277.28b / Shares 1.24b; r=6.0% [WACC]; 5y FCF grow -4.03% → 3.0% )
EPS Correlation: 13.85 | EPS CAGR: 6.91% | SUE: 0.80 | # QB: 0
Revenue Correlation: 54.02 | Revenue CAGR: 2.87% | SUE: 0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-6.60 | Chg30d=-442.82% | Revisions=-76% | Analysts=19
EPS next Quarter (2026-09-30): EPS=1.80 | Chg30d=-21.88% | Revisions=-6% | Analysts=18
EPS current Year (2026-12-31): EPS=-0.82 | Chg30d=-109.59% | Revisions=-81% | GrowthEPS=-110.0% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=9.61 | Chg30d=+0.34% | Revisions=-24% | GrowthEPS=+1272.9% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -81%